Vascarta and CUNY Achieve Promising Preclinical Success in Glioblastoma Treatment Vascarta Inc. and CUNY have unveiled a groundbreaking study showing that their novel drug candidate, STO-1, effectively targets and eliminates glioblastoma cells without causing autoimmune reactions.

Vascarta and CUNY Achieve Promising Preclinical Success in Glioblastoma Treatment #USA #Glioblastoma #Vascarta #Summit #CUNY

New Transdermal Curcumin Gel Shows Promise for Acute Pain Relief in Sickle Cell Disease Vascarta Inc. has unveiled a groundbreaking transdermal curcumin gel that alleviates acute pain in sickle cell disease, paving the way for innovative treatments.

New Transdermal Curcumin Gel Shows Promise for Acute Pain Relief in Sickle Cell Disease #USA #sickle_cell_disease #Vascarta #Summit #Curcumin_Gel

Vascarta Successfully Completes Phase 1 Trial of VAS-101 for Osteoarthritis Treatment Vascarta Inc. announces the successful completion of its Phase 1 trial for VAS-101, a promising treatment for osteoarthritis pain relief.

Vascarta Successfully Completes Phase 1 Trial of VAS-101 for Osteoarthritis Treatment #United_States #Osteoarthritis #Vascarta #VAS-101 #Summit

Vascarta Strengthens Leadership with Appointment of Dr. Janet Loesberg Vascarta has appointed Dr. Janet Loesberg as their Fractional Chief Strategy Officer, enhancing their strategic direction and portfolio management.

Vascarta Strengthens Leadership with Appointment of Dr. Janet Loesberg #United_States #Vascarta #Summit #Vasceptor #Dr._Loesberg

Vascarta's Vasceptor® Receives Key FDA Orphan Drug Status for Sickle Cell Treatment Vascarta Inc. has been granted Orphan Drug Designation for Vasceptor®, marking a significant advancement in treating Sickle Cell Disease.

Vascarta's Vasceptor® Receives Key FDA Orphan Drug Status for Sickle Cell Treatment #United_States #sickle_cell_disease #Vascarta #Summit #Vasceptor

Vascarta Launches Phase 1 Clinical Trial for VAS-101 Treatment in Sickle Cell Disease Vascarta has initiated a groundbreaking Phase 1 clinical study of VAS-101, a novel topical curcumin gel, aimed at treating sickle cell disease in the U.S.

Vascarta Launches Phase 1 Clinical Trial for VAS-101 Treatment in Sickle Cell Disease #United_States #Hollywood,_Florida #sickle_cell_disease #Vascarta #VAS-101

Vascarta Starts Phase I Trial of Innovative Curcumin Gel for Osteoarthritis Vascarta has initiated a Phase I clinical study of VAS101, a topical gel for treating osteoarthritis. The study aims to evaluate safety and efficacy over 28 days.

Vascarta Starts Phase I Trial of Innovative Curcumin Gel for Osteoarthritis #Australia #Osteoarthritis #Vascarta #Perth #VAS101

Reversing Aging Signs: VAS101's Groundbreaking Effects on Health A recent study in GeroScience highlights VAS101's promise as a curcumin transdermal formulation that reverses aging effects in mice.

Reversing Aging Signs: VAS101's Groundbreaking Effects on Health #USA #Vascarta #Curcumin #Summit #VAS101

Breakthrough Transdermal Drug Candidate VAS-101 Offers Hope for Sickle Cell Patients Vascarta is set to initiate clinical trials for VAS-101, a transdermal treatment for sickle cell disease, which shows promise in alleviating pain and inflammation.

Breakthrough Transdermal Drug Candidate VAS-101 Offers Hope for Sickle Cell Patients #USA #Sickle_Cell #Vascarta #VAS-101 #Summit

Vascarta and CUNY Join Forces to Revolutionize Chemotherapy for Cancer Patients Vascarta and CUNY are collaborating to enhance the efficacy and safety of cancer treatment, utilizing innovative linker chemistry for improved chemotherapeutics.

Vascarta and CUNY Join Forces to Revolutionize Chemotherapy for Cancer Patients #USA #cancer_therapy #Vascarta #CUNY #Summit,_New_Jersey

VAS-101 Emerges as a Breakthrough in Red Blood Cell Biopreservation A revolutionary study reveals that VAS-101 significantly enhances the preservation and lifespan of stored red blood cells, promising a leap in transfusion medicine.

VAS-101 Emerges as a Breakthrough in Red Blood Cell Biopreservation #United_States #Vascarta #Curcumin #VAS-101 #Summit

Revolutionary Curcumin Gel from Vascarta Could Transform Treatment for Sickle Cell Disease Vascarta Inc. presents promising new research at the American Society of Hematology Conference, highlighting a curcumin gel's potential to benefit sickle cell disease patients.

Revolutionary Curcumin Gel from Vascarta Could Transform Treatment for Sickle Cell Disease #USA #San_Diego #Sickle_Cell #Vascarta #Curcumin